According to the Xintiandi announcement, on July 21, 2026, the company received the “Chemical Ingredient Marketing Application Approval Notice” for the drug amlodipine benzenesulfonate approved and issued by the State Drug Administration. The registration number is Y20240001499, which is valid for 18 months. The notice is valid until July 20, 2031. This raw material can be used to treat high blood pressure, coronary heart disease, etc. This approval will enrich the company's product structure and enhance competitiveness, but pharmaceutical production and sales are affected by various factors, and there is uncertainty.

According to the Xintiandi announcement, on July 21, 2026, the company received the “Chemical Ingredient Marketing Application Approval Notice” for the drug amlodipine benzenesulfonate approved and issued by the State Drug Administration. The registration number is Y20240001499, which is valid for 18 months. The notice is valid until July 20, 2031. This raw material can be used to treat high blood pressure, coronary heart disease, etc. This approval will enrich the company's product structure and enhance competitiveness, but pharmaceutical production and sales are affected by various factors, and there is uncertainty.